Melatonin-and resveratrol-based multitarget-directed agents for Alzheimer's disease and photoswitchable muscular nicotinic receptor ligands
Alzheimer´s disease (AD) is a complex multifactorial illness with no effective treatment, characterized by irreversible global cognitive impairment. As only symptomatic treatment sare available with drugs acting at one single target, exploration of molecules active indifferent pathological targets i...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/10735 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/10735 |
| Access Level: | acceso abierto |
| Palabra clave: | 615.357(043.2) Melatonina Melatonin Endocrinología Farmacología (Medicina) 3205.02 Endocrinología |
| Sumario: | Alzheimer´s disease (AD) is a complex multifactorial illness with no effective treatment, characterized by irreversible global cognitive impairment. As only symptomatic treatment sare available with drugs acting at one single target, exploration of molecules active indifferent pathological targets is required. In this chapter, our objective was to develop new families of multitarget directed ligands (MTDLs) focused on some pathological pathways underlying AD, namely, oxidative stress and neuro inflammation. Thus, we design melatonin- and resveratrol-based MTDLs looking for activity in melatonin receptors (MT1-3Rs), monoaminoxidases (MAO-A/B), lipoxygenase-5 (LOX-5), and nuclear factor erythroid 2-related factor 2 (Nrf2). Considering the neuroprotective and neurogenic properties found in melatonin and resveratrol, we reasonably expected these activities in our MTDLs... |
|---|